A retrospective cohort study of more than 1200 patients who underwent bariatric surgery suggests a fully remote preoperative evaluation performed via telemedicine was noninferior to in-person evaluations for clinical outcomes and health care utilization.
The risk of diabetes was reduced by approximately 50% in both the vigorous and moderate aerobic exercise groups compared with the nonexercise group.
A sugary drinks tax in England may have prevented over 5,000 cases of obesity a year in older girls, but had no significant association with obesity levels in year six boys or younger children.
With up to 40 years of follow-up, a retrospective study of matched pairs is providing an overview of the long-term risks and benefits of bariatric surgery in people with overweight or obesity.
Participants in the Tromsø study with both obesity and moderately high/high waist circumference at baseline had increased odds of being frail compared with those in the normal range.
Using data from the STEP 5 trial, investigators provide new insight into the effects of semaglutide 2.4 mg on hunger and cravings among people with overweight and obesity, with results also shedding light on how these effects correlate to weight loss in the trial.
Using data from more than 500 patients with more than 6 years of follow-up suggests total caloric intake may be more effective for reducing weight loss than increasing the time between meals.
A posthoc analysis of the VITAL study suggests the potential benefit of vitamin D supplementation could depend on a person's body mass index, with results indicating a decreased response to therapy as BMI category increased.
A secondary analysis of a cluster RCT indicated the Texas Sprouts intervention led to improvements in glucose control and reduced LDL-C in high-risk schoolchildren.
MAFLD-lean and MAFLD-diabetes subgroups recorded a higher risk of all-cause and disease-specific mortality compared to the MAFLD-overweight/obese group.
Published in Pediatrics on January 9, the document represents the first comprehensive guideline from the American Academy of Pediatrics in more than a decade and the first ever on the evaluation and management of obesity in those aged 2 years and older.
Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.
Using data from more than 25,000 preschool-aged children in Sweden provides an overview in trends of weight gain and BMI changes that may have impacted pediatric populations during the COVID-19 pandemic.
There was no differences observed in total weight loss at both 6 and 18 months in the fecal microbiota transplantation and placebo groups.
A continued discussion with Dr. Bays on anti-obesity therapies down the line and where they might be in the near future.
Anti-obesity medications have the potential for significant weight reduction, but the development of newer agents may lead to an even greater change in obesity care.
In her SDPA 2022 presentation interview, Dr. Katta explores gaps in knowledge regarding the connection between skin disease and dietary health, as well as ways to address these concerns.
The emergence of weight loss agents like tirzepatide and an FDA Fast Track designation announced days earlier, endocrinologists were excited to discuss what's happening at Pri-Med Midwest 2022.
As the age of diagnosis for pre and type 2 diabetes continues to decrease, Dr. Tina Thethi believes in focusing on reducing risk factors to prevent further complications.
The ongoing buzz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a summit at Pri-Med Midwest 2022.
"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.
Semaglutide (Wegovy) has drawn attention for its indication of weight loss. Recently, however, the focus has shifted to the data surrounding tirzepatide.
Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.
Primary Care Physicians (PCPs) play a crucial role in endorsing lifestyle counseling and facilitating integrative care for their patients.
"Less than 2 or 3% of individuals with obesity—who are candidates for pharmacotherapy—actually receive a medication," Dr. Robert Kushner explains in an interview.
